Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a clinical-stage biotechnology company pioneering innovative cancer and viral infection ...
Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide ...
A new study shows how an anticancer drug triggers an "outside in" signal that gets it sucked into a cancer cell. The work, published Jan. 29 in Nature Communications, reveals a new signaling mechanism ...
Cell-cell interactions help drive tolerogenic or inflammatory responses to the maelstrom of antigens passing through the gut.
Researchers have developed a computer model to help scientists identify tumor-fighting immune cells in patients with lung cancer treated with immune checkpoint inhibitors.
Acquisition to strengthen key pillar of BioNTech's oncology strategy aimed at establishing BNT327 as a pan-tumor technology platform for the treatment of advanced cancersWith the closing of the transa ...
Ipsen and Sutro Biopharma entered a global licensing deal for STRO-003, an ADC targeting ROR1, overexpressed in cancers, ...
This important study provides solid evidence to support the anti-tumor potential of citalopram, originally an anti-depression drug, in hepatocellular carcinoma (HCC). In addition to their previous ...
Your immune system creates specific defenses called antibodies against the imitation pathogen — known as an antigen — introduced by the vaccine. "An antigen might be a germ that has been killed or ...
FAB have got the rolls Royce of AI technology in the antibody space not only for humans but animals too etc. Once the herd arrive this is 10x as a minimum. Bring on the news. Let's face it most ...
The transcription factor regulatory network in Pseudomonas aeruginosa is complex and involves multiple regulators that respond to various environmental signals and physiological cues by regulating ...
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...